Clinical, hematologic, and immunologic effects of interleukin-10 in humans

We conducted a double-blind, placebo-controlled study to investigate the safety, pharmacokinetics, and immunological properties of interleukin-10 (IL-10) administration in healthy humans. Volunteers received a single intravenous bolus injection of recombinant human IL-10 (1, 10, or 25μg/kg) or placebo. Cytokine production in whole blood and peripheral blood mononuclear cells (PBMC) was assessed before and 3, 6, 24, and 48 hr after the injection. Peak serum concentrations of IL-10 (15±1.1, 208±20.1, and 505±22.3 ng/ml) occurred after 2–5 min for 1, 10, and 25μg/kg IL-10, respectively. The terminal-phase half-life was 3.18 hr. A transient leukocytosis (24–63% above baseline) was observed 6 hr after injection, which coincided with a dose-dependent decrease (12–24%) in neutrophil superoxide generation. There was a marked inhibition (60–95%) of endotoxin-induced IL-6 production from whole blood in each group receiving IL-10. Production of IL-8 in endotoxin-stimulated blood was reduced in the 10μg/kg group. In PBMC stimulated with phytohemagglutinin and phorbol ester, there was a decrease (72–87%) in interferon-γ (IFNγ) production 6 hr after IL-10 with a return to pre-IL-10 levels after 24 hr. This reduction was only partially associated with a decrease in the number of CD2-bearing cells. We conclude that IL-10 administration into humans is without significant side effects, and a single injection reducesex vivo production of IL-6, IL-8, and IFNγ.

[1]  T. Hirano,et al.  Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Dinarello,et al.  Interleukin‐1 (IL‐1) receptor blockade reduces endotoxin and Borrelia burgdorferi‐stimulated IL‐8 synthesis in human mononuclear cells , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  G. Constantin,et al.  Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide , 1993, The Journal of experimental medicine.

[4]  F. Houssiau,et al.  Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. , 1988, Arthritis and rheumatism.

[5]  P. Ward,et al.  Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. , 1993, Journal of immunology.

[6]  J. Elias,et al.  Differential interleukin 1 elaboration by unfractionated and density fractionated human alveolar macrophages and blood monocytes: relationship to cell maturity. , 1985, Journal of immunology.

[7]  V. Bocci.  Interleukins. Clinical pharmacokinetics and practical implications. , 1991, Clinical pharmacokinetics.

[8]  T. Mosmann,et al.  Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Hirano,et al.  Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Dinarello,et al.  Ultrafiltration to remove endotoxins and other cytokine-inducing materials from tissue culture media and parenteral fluids. , 1990, BioTechniques.

[11]  J. Banchereau,et al.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Klein,et al.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. , 1994, The New England journal of medicine.

[13]  C. Dinarello,et al.  Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. , 1991, Blood.

[14]  W. Henderson,et al.  Stimulation of neutrophil oxygen-dependent metabolism by human leukocytic pyrogen. , 1979, The Journal of clinical investigation.

[15]  G. Tosato,et al.  IL-10 inhibits human T cell proliferation and IL-2 production. , 1992, Journal of immunology.

[16]  L. Shapiro,et al.  Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. , 1993, The Journal of infectious diseases.

[17]  R. Nordan,et al.  A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. , 1986, Science.

[18]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[19]  J. Meer,et al.  Interleukin-1 beta in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. , 1988, Lymphokine research.

[20]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease , 1989 .

[21]  J. Meer,et al.  Concentrations of Immunoreactive Human Tumor Necrosis Factor Alpha Produced by Human Mononuclear Cells In Vitro , 1988, Journal of leukocyte biology.

[22]  L. Aarden,et al.  Interleukin 6 is involved in interleukin 1‐induced activities , 1988, European journal of immunology.

[23]  J. Gauldie,et al.  Interferon f 32 / B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells ( inflammation / acute phase reactants / gene regulation ) , 2022 .

[24]  S. Meuer,et al.  Interleukin 10 and immune restoration in common variable immunodeficiency , 1993, The Lancet.

[25]  C G Figdor,et al.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.

[26]  C. Dinarello,et al.  Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. , 1990, Blood.

[27]  L. Shapiro,et al.  A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. , 1995, Journal of immunology.

[28]  R. de Waal Malefyt,et al.  IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. , 1992, Journal of immunology.

[29]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.